Join us on Thursday, February 11^th for this CME-accredited webinar
5:00 PM – 6:00 PM ET

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Sumitomo Dainippon Pharma Oncology Inc and Taiho Oncology Inc.

Not an official event of the 2021 Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2021 Gastrointestinal Cancers Symposium.

Agenda

MODULE 1: Current Management of Metastatic Colorectal Cancer (mCRC) with BRAF V600E Mutations

• Indications for molecular testing in patients with mCRC; prevalence of BRAF V600E mutations and effect on prognosis
• Design, eligibility criteria and primary and secondary endpoints evaluated in the Phase III BEACON CRC trial comparing encorafenib/cetuximab with or without binimetinib to irinotecan/cetuximab or FOLFIRI/cetuximab for patients with mCRC and BRAF V600E mutations
• Published efficacy and safety findings from BEACON CRC; FDA approval and appropriate integration of encorafenib/cetuximab for the treatment of mCRC with BRAF mutations
• Spectrum and frequency of toxicities observed with encorafenib/cetuximab; optimal management strategies
• Early findings with and ongoing evaluation of earlier use of BRAF-targeted therapy for mCRC (eg, ANCHOR CRC trial)
• Proposed design of the Phase III BREAKWATER trial evaluating encorafenib/cetuximab as first-line therapy

MODULE 2: Key Considerations in the Selection and Sequencing of Therapies for Patients with mCRC; Novel Investigational Approaches

• Correlation between the right or left location of the primary tumor and outcomes with specific systemic therapies for patients with mCRC
• Rational incorporation of EGFR-antibody therapy into current treatment algorithms for patients with mCRC
• Long-term efficacy and safety findings with regorafenib and TAS-102 and clinical, biologic and practical factors in the sequencing of these agents
• Available data with and potential role of TAS-102 in combination with other systemic agents for mCRC or for earlier-stage disease
• Mechanism of action of napabucasin; available efficacy and safety data with napabucasin monotherapy in unselected patients with mCRC and in the prespecified subgroup with elevated pSTAT3
• Design, eligibility, primary and secondary endpoints and estimated completion date of the Phase III CanStem303C trial evaluating napabucasin in combination with FOLFIRI for previously treated mCRC
• Other promising agents and strategies under investigation in mCRC

MODULE 3: Optimal Incorporation of Immune Checkpoint Inhibitors into Therapy for mCRC

• Key efficacy and safety outcomes from the Phase III KEYNOTE-177 trial comparing pembrolizumab to standard chemotherapy for patients with newly diagnosed microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) mCRC; FDA approval and current clinical role
• Rational incorporation of nivolumab, pembrolizumab and nivolumab/ipilimumab into the treatment of MSI-H/dMMR mCRC
• Ongoing investigation of immune checkpoint inhibitors in combination with other systemic approaches (eg, chemotherapy, targeted therapy) for MSI-H/dMMR early and advanced CRC
• Biologic rationale for, available data with and ongoing investigation of regorafenib in combination with nivolumab for patients with microsatellite stable (MSS) mCRC
• Findings from other early-phase studies (eg, REGOMUNE, CAVE, ILLUMINATE-206) and ongoing evaluation of regimens combining immune checkpoint inhibition with different systemic therapies for MSS mCRC

MODULE 4: Current and Future Directions in the Management of HER2-Positive mCRC

• Frequency of HER2 amplification in advanced CRC; indications for HER2 testing and optimal testing platform
• Available data with HER2-directed approaches (eg, pertuzumab/trastuzumab, lapatinib/ trastuzumab, tucatinib/trastuzumab, trastuzumab emtansine) to therapy for mCRC
• Key efficacy findings from the Phase II DESTINY-CRC01 study of trastuzumab deruxtecan for patients with HER2-expressing mCRC; potential clinical role of this agent
• Spectrum, incidence and severity of toxicities, including interstitial lung disease, with trastuzumab deruxtecan in the DESTINY-CRC01 trial
• Ongoing clinical trials evaluating anti-HER2 approaches for patients with mCRC

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare professionals involved in the treatment of colorectal cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Coordinate comprehensive biomarker analysis for patients diagnosed with metastatic colorectal cancer (mCRC), and use the results of appropriate testing to guide evidence-based care.
• Develop a long-term plan for the selection and sequencing of therapies for patients diagnosed with mCRC, considering biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals of treatment.
• Appreciate published research data documenting the efficacy of combined BRAF/EGFR inhibition for relapsed/refractory mCRC with a BRAF V600E mutation, and optimally incorporate this therapeutic strategy into patient care.
• Evaluate available data with and the FDA approvals of nivolumab, pembrolizumab and the combination of nivolumab/ipilimumab for microsatellite instability-high or mismatch repair-deficient mCRC, and optimally select patients for treatment with anti-PD-1-based therapy.
• Recognize available data with anti-HER2 therapy for patients with HER2-positive mCRC, and consider the current and future role of various investigational approaches.
• Recall new data with investigational agents and strategies demonstrating promising activity in CRC, and use this information to refer appropriate patients for participation in ongoing trials.

CME Credit Form
A CME credit form will be emailed to participants within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Ciombor — Consulting Agreements: Merck, Natera Inc; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Daiichi Sankyo Inc, Incyte Corporation, Merck, NuCana, Pfizer Inc. Prof Van Cutsem — Consulting Agreements: Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biocartis, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, GlaxoSmithKline, Halozyme Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Novartis, Pierre Fabre, Roche Laboratories Inc, Servier, Sirtex Medical Ltd, Taiho Oncology Inc; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Novartis, Roche Laboratories Inc, Servier.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Sumitomo Dainippon Pharma Oncology Inc and Taiho Oncology Inc.